Last reviewed · How we verify
Pemetrexed Disodium for Injection
Pemetrexed is a folate antagonist that inhibits multiple enzymes involved in nucleotide synthesis, disrupting DNA and RNA production in cancer cells.
Pemetrexed is a folate antagonist that inhibits multiple enzymes involved in nucleotide synthesis, disrupting DNA and RNA production in cancer cells. Used for Metastatic non-small cell lung cancer, Malignant pleural mesothelioma, Locally advanced or metastatic urothelial cancer.
At a glance
| Generic name | Pemetrexed Disodium for Injection |
|---|---|
| Also known as | Pemetrexed Disodium |
| Sponsor | Allist Pharmaceuticals, Inc. |
| Drug class | Antifolate antimetabolite |
| Target | Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Pemetrexed disodium is a multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, key enzymes in the folate pathway required for purine and pyrimidine synthesis. By blocking these enzymes, it prevents the formation of nucleotides necessary for DNA and RNA synthesis, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells.
Approved indications
- Metastatic non-small cell lung cancer
- Malignant pleural mesothelioma
- Locally advanced or metastatic urothelial cancer
Common side effects
- Myelosuppression (neutropenia, anemia, thrombocytopenia)
- Nausea and vomiting
- Fatigue
- Mucositis
- Diarrhea
- Rash
Key clinical trials
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
- Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC (PHASE2)
- A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) (PHASE3)
- Phase III Study of AK112 for NSCLC Patients (PHASE3)
- A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) (PHASE3)
- Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients (PHASE2)
- A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC (PHASE1)
- Phase 3 Clinical Study of AK112 for NSCLC Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pemetrexed Disodium for Injection CI brief — competitive landscape report
- Pemetrexed Disodium for Injection updates RSS · CI watch RSS
- Allist Pharmaceuticals, Inc. portfolio CI